Cutaneous manifestations following COVID‐19 vaccination: a multicentric descriptive cohort

Massip, Edouard; Marcant, Pierre; Font, Guillaume; Faiz, Sarah; Duvert‐Lehembre, S.; Alcaraz, I.; Vermersch‐Langlin, A.; Véron, Marie; Macaire, Camille; Faure, Karine; Vuotto, Fanny; Staumont‐Sallé, D.; Dezoteux, F.

doi:10.1111/jdv.17883

Cited by 6 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the duration of systemic skin reactions, major findings [ 22 , 23 , 26 ] were summarized in the Table S6 in the Online Supplementary Document . We reported on inconsistent results.…”

Section: Resultsmentioning

confidence: 99%

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background Understanding the incidence pattern of cutaneous reactions is crucial for promoting COVID-19 vaccination. We aimed to report the global incidence pattern of, and factors associated with common cutaneous reactions related to COVID-19 vaccination in real-world settings. Methods We searched five databases (PubMed, Web of Science, Embase, CNKI, and Wanfang) from inception to May 13, 2022, for studies reporting the incidence of common cutaneous reactions related to COVID-19 vaccines in real-world settings. The outcomes were the systematic skin reactions (rash and urticaria) and the local injection site reactions (pain, swelling, redness, and erythema). We conducted random-effects meta-analyses and explored associated factors using multi-step statistical analyses. Results We included 35 studies and assessed 2 549 968 participants from 23 countries. The pooled incidence of overall systemic skin reactions was 3.8% (95% confidence interval (CI) = 2.4%-5.5%) with short duration (about one week). Specifically, the pooled incidence rates of rash and urticaria were 3.0% (95% CI = 2.1%-3.9%) and 1.1% (95% CI = 0.7%-1.5%), respectively. For overall local injection site reactions, the pooled incidence was 72.4% (95% CI = 65.7%-78.7%) with short duration (1 to 4.5 days). Except for local pain (72.2%, 95% CI = 65.3%-78.5%), other localized reactions had low incidence, including swelling (13.3%, 95% CI = 9.5%-17.7%), redness (11.5%, 95% CI = 5.7%-19.0%), and erythema (5.8%, 95% CI = 0.7%-15.4%). Geographically, different distribution patterns were observed for these reactions. Regarding associated factors, mRNA vaccines showed lower incidence of urticaria ( P < 0.001). Asia population showed higher incidence of urticaria ( P < 0.001). We observed lower incidence rates of overall local injection site reactions and pain among inactivated vaccines ( P < 0.001). We found no significant difference among reactions between the first and the second dose of vaccines. Conclusions We examined the global incidence pattern of common cutaneous reactions related to COVID-19 vaccination and found low incidence and short duration of systemic skin reactions and local injection site reactions (except for pain); discrepancies in these reactions were observed across different vaccine types. The cutaneous side effects related to COVID-19 vaccination do not seem to cause concern. Registration PROSPERO: CRD42021258012.

show abstract

Section: Resultsmentioning

confidence: 99%

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…14 Moreover, there have been several adverse cutaneous reactions (ACR) that have been associated with COVID-19 vaccination including local injection site reactions, morbilliform eruptions, urticaria and angioedema as well as delayed local reactions. [18][19][20][21] Lebanon registered its first case of COVID-19 on February 20, 2020. To date, over 1,200,000 cases have been recorded according to the Lebanese ministry of public health.…”

Section: Introductionmentioning

confidence: 99%

“…There seems to be a trend linking some types of rashes, such as pernio‐like eruption, with an effective antiviral immune response and a better prognosis 14 . Moreover, there have been several adverse cutaneous reactions (ACR) that have been associated with COVID‐19 vaccination including local injection site reactions, morbilliform eruptions, urticaria and angioedema as well as delayed local reactions 18–21 …”

Section: Introductionmentioning

confidence: 99%

Dermatological manifestations associated with COVID‐19 and COVID‐19 vaccination: results from the Lebanese COVID registry

Chrabieh,

Haddad,

Salameh

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

BackgroundA number of cutaneous manifestations and adverse cutaneous reactions have been associated with COVID‐19 infection and vaccine.ObjectivesA Lebanese national registry was established to characterize the dermatologic manifestations and adverse cutaneous reactions associated with COVID‐19 infection and vaccination in a sample of the Lebanese population.MethodsAn observational cross‐sectional study was conducted via a web‐based clinical form distributed to physicians wishing to report their cases from May 2021 till May 2022.ResultsIn total, 142 patients were entered in the registry, of which 133 were adults and nine were pediatric patients. The main dermatological manifestations reported with COVID‐19 infection in the adult group were urticaria (32.9%), telogen effluvium (21.4%), morbilliform (10%), and papulosquamous (8.6%) eruptions. Urticaria was the most common adverse cutaneous reaction to the vaccine (33%). Interestingly, herpes zoster was triggered in 12 patients post vaccination in our series with this finding more frequently seen in patients above the age of 41 (P = 0.013). In the pediatric group, the most reported dermatological findings associated with COVID‐19 infection were malar erythema (25%) and telogen effluvium (25%). One 16‐year‐old patient developed lichen planus after one dose of a COVID‐19 vaccine. No deaths were reported in both age groups.ConclusionThis Lebanese registry adds more robust evidence that clinical manifestations of the COVID‐19 virus and vaccine are diverse. More studies are necessary to establish the pathophysiology of these dermatological findings in the context of COVID‐19 infection and vaccination.

show abstract

“…To the Editor: Several dermatologic manifestations have been reported in association with SARS-CoV-2 infection, affecting 4 to 20.4% of patients [1]. Although immune-mediated dermatoses triggered by anti-SARS-Cov-2 vaccines have been published, very few bullous pemphigoids (BP) triggered by SARS-Cov-2 infection have been reported [2].…”

mentioning

confidence: 99%

“…Although most cases are idiopathic, several trigger factors have been described in the literature, such as drugs, ultraviolet radiation, burns, trauma, and vaccines. Furthermore, cases of BP developed following viral infections have been described [1].…”

mentioning

confidence: 99%

Bullous pemphigoid after the second SARS-CoV-2 infection

Correia,

Alpalhao,

Soares-de-Almeida

et al. 2023

DOJ

View full text Add to dashboard Cite

Cutaneous manifestations following COVID‐19 vaccination: a multicentric descriptive cohort

Cited by 6 publications

References 9 publications

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

Dermatological manifestations associated with COVID‐19 and COVID‐19 vaccination: results from the Lebanese COVID registry

Bullous pemphigoid after the second SARS-CoV-2 infection

Contact Info

Product

Resources

About